Services Portfolio Management Strategy

Pharma portfolio strategy

Scitaris supports biotech and pharma leaders with science-driven portfolio management consulting. From due diligence to asset positioning, we provide objective insight that helps you act with speed and confidence.

Start the conversation

Clarity for complex business decisions

Pharma portfolio strategy too often stalls due to noise, bias, and uncertainty. Our PhD-trained team combines scientific analysis and business acumen to strip away the clutter so you can move forward with confidence.

>100 due diligences performed

Provided strategic advice on deals covering (pre-)clinical and regulatory aspects

84% trial prediction accuracy

We predicted clinical efficacy trial outcomes with 84% accuracy

Multi-billion value generation

Our portfolio strategies have led to transacted assets worth billions

Asset positioning support

Successful out-licensing depends on framing assets in a way that addresses partner concerns and highlights differentiation. We anticipate potential questions and prepare marketing materials, including decks, that accelerate partnering discussions and increase the probability of a successful transaction.

View service flyer

Drug due diligence consulting

Our collaborative, systematic approach to technical and commercial due diligence is comprehensive across all relevant dimensions while remaining efficient and fast — helping you get ahead in competitive processes. We coordinate Q&A and support structuring a deal based on identified risks, giving you the confidence to move forward.

Asset search and evaluation

Our comprehensive screening process identifies strategically aligned growth opportunities across 100k+ biopharma NMEs and 20k companies worldwide. Our science-driven S&E approach has been validated in practice, with numerous identified opportunities leading to successful deals and value generation.

Portfolio management challenge

A mid-sized biotech was struggling with pipeline setbacks that put both growth plans and investor confidence at risk. The team needed to secure new opportunities quickly to restore momentum and credibility.

Scitaris solution

Scitaris deployed our science-driven asset search and evaluation framework, drawing on proprietary algorithms and curated databases to scan more than 70,000 programs worldwide.

Results

Within weeks, the company licensed a high-value program that revitalized its portfolio and reassured stakeholders. The strengthened pipeline supported critical decision-making and contributed to a 15-fold increase in share price over the following year.

Joe Truitt

CEO, iECURE Inc. (former CEO, Achillion Pharma Inc. & Biospecifics Technologies Inc.)

The Scitaris team were tremendous partners in our efforts to evaluate new business opportunities to add to our product portfolio.

Their insight across all of the critical segments – scientific data, clinical path, regulatory, commercial, competitive landscape – made the process efficient and productive for our Management team. I would recommend this group for anyone needing to make strategic additions to their company offerings.

Matt Call

COO, iTeos Therapeutics Inc.

Over the last years, I have had the pleasure to work with Scitaris on some key strategic projects for our firm and was, without exception, extremely impressed by the exceptional quality of the firm's work.

They never relied on ‘off the shelf solutions’ for challenges but unceasingly came up with innovative and tailor-made approaches, in all cases adding real value to the company. This, coupled with his exceptionally high standards of quality, deep industry knowledge and strong managerial skills, positions Scitaris as one of the top advisors in the industry.

Wolfgang Fischer

COO, Affimed

Over the years, we have fostered a long-standing relationship with the Scitaris team as they hit the sweet spot of deep scientific understanding, industry experience and strategic thinking in our highly complex and fast-paced world of Immuno-Oncology.

They have supported us on various questions ranging from corporate and business development strategy to asset-level indication strategy. I would not hesitate to recommend them to anyone with pressing questions in the realm of R&D strategy.

Mike Andriole

CFO & CBO, Chimerix Inc. (former CBO, Endocyte Inc.)

Scitaris’ intellect and passion for the work is remarkable.

Moreover, it is not every day you get to work with talented people that you really enjoy being in their company and interacting on a daily basis — this is certainly true with all of the team.

FAQs

What is the overall process, and how customizable is it?

Our opportunity screens start from a proprietary, comprehensive database combining asset, company, and scientific information. We apply client-specific filters and rankings to generate a prioritized asset option space, which is then analyzed at varying levels of depth to further focus on the best possible opportunities. The process is fully customizable.

Can we include side entries in the analysis?

Yes. Side entries and inbound lists from investment banks can be integrated at any stage.

How does pricing work? Do you offer success-based or project-based fees?

We invoice only for the actual effort spent, without success-based fees, to ensure full objectivity for our clients.

How long does a typical engagement take?